A big setback for Seattle Genetics Inc.'s vadastuximab talirine (SGN-CD33A) in a Phase III acute myeloid leukemia trial will put more pressure on the company's expansion strategy for the currently-marketed lymphoma drug Adcetris (brentuximab vedotin) to drive growth in the near-term.
The Bothell, Washington-based biotech announced June 19 that it is discontinuing all clinical trials studying vadastuximab talirine, including the Phase...